DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Trastuzumab deruxtecan|DRUG: Capecitabine|DRUG: Lapatinib|DRUG: Trastuzumab
Sponsor: Daiichi Sankyo
Collaborators: Daiichi Sankyo Co., Ltd.|AstraZeneca